Privacy & Cookie Policy

ThirtyFiveBio were delighted to make our data debut at the American Association for Cancer Research (AACR) 2023 conference where our CEO, James Westcott, presented our groundbreaking data in a scientific poster. Our team and network of academic institutions, research organizations, and industry partners have been developing and testing our innovative approach of antagonising GPR35 to tackle digestive...

  ThirtyFiveBio Emerges From Stealth with Presentation of First Data from GPR35 Antagonist Program at American Association for Cancer Research (AACR) Annual Meeting 2023    Third Company Created by M:M Bio and Jointly Incubated by Canaan Partners has Raised $20 Million to Date  Pioneering a New Precision Medicine Approach to Gastrointestinal Diseases and Cancers through...